Latest Administration News

Argosy Minerals Limited reported a net cash outflow in its December 2024 quarter, driven by exploration and evaluation expenses, ending with nearly $6 million in cash reserves.

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

ENRG Elements Limited reported a $586,000 net cash outflow for the December quarter, offset by a $2.02 million equity raise, boosting its cash reserves to $2.52 million.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

K-TIG Limited is set to transform its business with a $7–10 million capital raise to acquire US-based Metal Powder Works, issuing performance-based vendor shares that an independent expert deems fair and reasonable.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

Kali Metals Limited has acknowledged a delay in lodging director interest notices due to an administrative oversight, reaffirming its commitment to ASX compliance and outlining existing disclosure procedures.

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

Income Asset Management delivered steady revenue of $4.0 million in Q2 FY2025 alongside significant growth in funds under administration and client accounts, while retiring $10 million in debt to reduce interest costs.

BOD Science has executed an asset sale deed transferring critical intellectual property rights to Optimus Salvus, marking a pivotal step in its Deed of Company Arrangement process.

Clarity Pharmaceuticals has secured a second FDA Fast Track Designation for its 64Cu-SAR-bisPSMA diagnostic agent, aiming to revolutionize prostate cancer imaging and speed regulatory approval.